Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CardioTech wins approval to export coronary bypass graft
Approval by the notified body for a CE Mark would allow CardioPass to be marketed and sold in all EU countries as well as other countries worldwide that
Approval by the notified body for a CE Mark would allow CardioPass to be marketed and sold in all EU countries as well as other countries worldwide that
The new office is expected to allow MDS Pharma Services to better serve the Japanese pharmaceutical and biotechnology markets, and further enable growth opportunities both in Japan and
The Phase Ib clinical trial is designed to evaluate safety and to establish a maximum-tolerated dose of carfilzomib in combination with lenalidomide and dexamethasone on a 28 day
According to the new guidelines children as young as eight with LDL, or ‘bad’, cholesterol of 190mg per deciliter, or those with LDL of 160mg and a family
According to the survey, pharma companies are largely shifting away from selling medicines and are focusing on promoting health outcomes through initiatives like raising patients’ long-term use of
According to Michael Leavitt, secretary of the US Department of Health and Human Services (HHS), the regulatory agencies in the US, EU and Australia will jointly plan, allocate
The Bioheart 3370 heart failure monitor collects data from a range of vital sign monitoring devices, a weight scale and a voice-activated heart failure status questionnaire, and provides
The payment is made by the company’s co-development partner in Locteron, Biolex Therapeutics. The additional bridge financing will enable OctoPlus to secure one of the longer term financing
The positive results are from the treatment of 123 acute hereditary angioedema (HAE) attacks in 64 patients with different doses of Rhucin in the ongoing European and North
The European Medicines Agency (EMEA) agreed to Renovo performing two pivotal double blind, within patient, placebo controlled Phase III trials in scar revision surgery to establish efficacy. In